Halaven (eribulin) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, to extend Halaven’s license to include patients with unresectable liposarcomas who have received prior anthracycline containing therapy for advanced or metastatic disease. The opinion is based on phase III data demonstrating a median 7.2 month increase in...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
